Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2011, Article ID 907496, 5 pages
http://dx.doi.org/10.1155/2011/907496
Research Article

The Effect of Metformin on the Myocardial Tolerance to Ischemia-Reperfusion Injury in the Rat Model of Diabetes Mellitus Type II

1Institute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, Akkuratova Street 2, St. Petersburg 197341, Russia
2Institute of Experimental Medicine, Almazov Federal Heart, Blood and Endocrinology Centre, Akkuratova Street 2, St. Petersburg 197341, Russia
3Department of Pathophysiology, St. Petersburg Pavlov State Medical University, Lev Tolstoy Street 6/8, St. Petersburg 197022, Russia

Received 22 March 2011; Accepted 21 April 2011

Academic Editor: N. Cameron

Copyright © 2011 Ekaterina Kravchuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Hurst and R. W. Lee, “Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management,” Annals of Internal Medicine, vol. 139, no. 10, pp. 824–834, 2003. View at Google Scholar · View at Scopus
  2. G. Anfossi, I. Russo, K. Bonomo, and M. Trovati, “The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus,” Current Vascular Pharmacology, vol. 8, no. 3, pp. 327–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. UK Prospective Diabetes Study (UKPDS) Group, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” Lancet, vol. 352, no. 9131, pp. 854–865, 1998. View at Publisher · View at Google Scholar
  4. J. L. Sartoretto, G. A. N. Melo, M. H. C. Carvalho et al., “Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression,” Life Sciences, vol. 77, no. 21, pp. 2676–2689, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. C. Bhalla, K. F. Toth, E. Tan, R. A. Bhatty, E. Mathias, and R. V. Sharma, “Vascular effects of metformin: possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat,” American Journal of Hypertension, vol. 9, no. 6, pp. 570–576, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. R. J. Legtenberg, R. J. F. Houston, B. Oeseburg, and P. Smits, “Metformin improves cardiac functional recovery after ischemia in rats,” Hormone and Metabolic Research, vol. 34, no. 4, pp. 182–185, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. W. Calvert, S. Gundewar, S. Jha et al., “Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS- mediated signaling,” Diabetes, vol. 57, no. 3, pp. 696–705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Verma and J. H. McNeill, “Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts,” American Journal of Physiology, vol. 266, no. 2, pp. H714–H719, 1994. View at Google Scholar · View at Scopus
  9. M. Iwase, M. Kikuchi, and K. Nunoi, “Diabetes induced by neonatal streptozotocin treatment in spontaneously hypertensive and normotensive rats,” Metabolisml, vol. 36, no. 7, pp. 654–657, 1987. View at Google Scholar · View at Scopus
  10. M. Skrzypiec-Spring, B. Grotthus, A. Szelag, and R. Schulz, “Isolated heart perfusion according to Langendorff-Still viable in the new millennium,” Journal of Pharmacological and Toxicological Methods, vol. 55, no. 2, pp. 113–126, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. M. Galagudza, M. K. Nekrasova, A. V. Syrensky, and E. M. Nifontov, “Resistance of the myocardium to ischemia and the efficacy of ischemic preconditioning in experimental diabetes mellitus,” Neuroscience and Behavioral Physiology, vol. 37, no. 5, pp. 489–493, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Lavanchy, G. Christe, F. Cand, N. Wiernsperger, and J. Verdetti, “Effects of chronic treatment with glibenclamide and/or metformin on the resistance to ischaemia of isolated hearts from zucker diabetic fatty rats (ZDF/GMI-fa/fa),” British Journal of Diabetes and Vascular Disease, vol. 3, no. 5, pp. 375–380, 2003. View at Google Scholar · View at Scopus
  13. N. F. Wiernsperger, “50 years later: is metformin a vascular drug with antidiabetic properties?” British Journal of Diabetes and Vascular Disease, vol. 7, no. 5, pp. 204–210, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. D. G. Hardie, D. Carling, and M. Carlson, “The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?” Annual Review of Biochemistry, vol. 67, pp. 821–855, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. B. E. Kemp, D. Stapleton, D. J. Campbell et al., “AMP-activated protein kinase, super metabolic regulator,” Biochemical Society Transactions, vol. 31, no. 1, pp. 162–168, 2003. View at Google Scholar · View at Scopus
  16. G. S. Bhamra, D. J. Hausenloy, S. M. Davidson et al., “Metformin protects the ischemic heart by the akt-mediated inhibition of mitochondrial permeability transition pore opening,” Basic Research in Cardiology, vol. 103, no. 3, pp. 274–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. X. Hou, J. Song, X. N. Li et al., “Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway,” Biochemical and Biophysical Research Communications, vol. 396, no. 2, pp. 199–205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Dong, M. Zhang, S. Wang et al., “Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo,” Diabetes, vol. 59, no. 6, pp. 1386–1396, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. N. Li, X. Wang, Q. T. Zeng et al., “Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits,” Heart and Vessels, vol. 24, no. 6, pp. 446–453, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Li, J. C. Mamputu, N. Wiernsperger, and G. Renier, “Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin,” Diabetes, vol. 54, no. 7, pp. 2227–2234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Mamputu, N. Wiernsperger, and G. Renier, “Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation,” British Journal of Diabetes and Vascular Disease, vol. 3, no. 4, pp. 302–310, 2003. View at Google Scholar · View at Scopus